Filing Details
- Accession Number:
- 0000921895-23-000702
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-03-16 18:02:18
- Reporting Period:
- 2023-03-14
- Accepted Time:
- 2023-03-16 18:02:18
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1123494 | Harvard Bioscience Inc | HBIO | Laboratory Analytical Instruments (3826) | 043306140 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1195340 | I Alan Edrick | C/O Harvard Bioscience, Inc. 84 October Hill Rd. Holliston MA 01746 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-03-14 | 13,808 | $2.67 | 186,293 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2023-03-15 | 16,192 | $2.62 | 202,485 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct |
Footnotes
- This transaction was executed in multiple trades at prices ranging from $2.61 to $2.72, inclusive. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $2.57 to $2.68, inclusive. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- Includes (a) 38,259 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 17, 2022, immediately prior to the commencement of such meeting, and (ii) May 24, 2023 and (b) 164,226 shares of common stock held by the Report Person.